CORRECTION: Olainfarm’s Sales in September Are 8.21

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CORRECTION: Olainfarm’s Sales in September Are 8.21 Million Euros (growth rates in text amended)

Olaine, 2016-10-17 15:45 CEST (GLOBE NEWSWIRE) --  

September 2016, consolidated sales Sales, thsnd. EUR Changes to September 2015 Share in total sales
Latvia 2 418 15% 29%
Russia 2 043 -10% 25%
Ukraine 661 -44% 8%
The Netherlands 549 37% 7%
Belarus 544 15% 7%
Kazakhstan 456 281% 6%
UK 302 NA 4%
Spain 129 102% 2%
Denmark 119 NA 1%
Tajikistan 114 188% 1%
Other 879 -36% 11%
Total 8 214 2% 100%

Sales of pharmacy chain of SIA Latvijas aptieka in September 2016 were 1.6 million euros, which represents an increase by 12% compared to September 2015. Sixty-two pharmacies were operating during this period.  Sales of SIA Silvanols in September 2016 were .63 million euros, which is an increase by 17% compared to its sales in September of last year. SIA Silvanols sold its products to four European countries and with the help of AS Olainfarm also to Russia, Lithuania and Kazakhstan.  Sales of Tonus Elast in September were 0.53 million euros, and the company sold its products to 16 countries in three continents.

According to preliminary consolidated numbers for nine months of 2016, sales of AS Olainfarm have reached 78.51 million euros, which represents an increase by 8% compared to nine months period of 2015.  The biggest sales increase in nine months was achieved in Uzbekistan, where sales grew by 72%.  Sales to Turkmenistan and Ukraine grew by 38% each and sales to UK grew by 24%.  Major sales markets during this period were Russia, Latvia, Ukraine and Belarus.

9 months of 2016, consolidated sales Sales, thsnd. EUR Changes to 9 months of 2015 Share in total sales
Russia 22 989 -7% 29%
Latvia 19 200 15% 24%
Ukraine 12 149 38% 15%
Belarus 6 316 22% 8%
Kazakhstan 2 024 16% 3%
UK 1 891 24% 2%
Uzbekistan 1 780 72% 2%
The Netherlands 1 639 -67% 2%
Turkmenistan 1 067 38% 1%
Lithuania 956 16% 1%
Other 8 496 10% 11%
Total 78 507 8% 100%

Sales of pharmacy chain of SIA Latvijas aptieka in nine months were 13.9 million euros, which is an increase by 14% compared to same period of 2015.  Sales of SIA Silvanols in nine months of 2016 were 3.68 million euros, which represents an increase by 27% compared to nine months of last year, when Silvanols’ sales were 2.9 million euros. Products of SIA Silvanols were sold to eleven European countries and with the help of AS Olainfarm, also to Albania, Kosovo, Azerbaijan, Kazakhstan, Belarus and Russia. Sales of SIA Tonus Elast in four months was 2.66 million euros, its products were sold to 30 countries in four continents.

According to unconsolidated preliminary results, sales of AS Olainfarm in September 2016 were 6.47 million euro, which represents a reduction by 6% compared to the same period of 2015.  The biggest sales increase was achieved in Kazakhstan, where sales grew by 227%.  Sales to Tajikistan grew by 188%, but sales to Spain grew by 102%.  Significant shipments during this period were also made to the UK and Denmark.  Major sales markets of AS Olainfarm during this period were Russia, Latvia, Ukraine, The Netherlands and Belarus.  During September 2016 AS Olainfarm sold its products in 26 countries in two continents.

September 2016, unconsolidated sales Sales, thsnd. EUR   Changes to September 2015 Share in total sales
Russia 2 043 -10% 32%
Latvia 1 228 7% 19%
Ukraine 628 -47% 10%
The Netherlands 549 37% 8%
Belarus 544 11% 8%
Kazakhstan 391 227% 6%
UK 274 NA 4%
Spain 129 102% 2%
Denmark 119 NA 2%
Tajikistan 114 188% 2%
Other 451 -61% 7%
Total 6 470 -6% 100%

According to unconsolidated preliminary results, sales of AS Olainfarm in nine months of 2016 were 66.07 million euros, which represents an increase by 3% compared to nine months of 2015.  The biggest sales increase during this period was achieved in Uzbekistan, where sales grew by 72%.  Sales to Turkmenistan grew by 38%, while sales to Ukraine grew by 37%.  Majors sales markets in nine months of this year were Russia, Ukraine, Latvia and Belarus. In total during this period AS Olainfarm sold its products to 39 countries in four continents.  

9 months of 2016, unconsolidated sales Sales, thsnd. EUR Changes to 9 months of 2015 Share in total sales
Russia 22 587 -8% 34%
Ukraine 12 032 37% 18%
Latvia 9 916 8% 15%
Belarus 6 293 22% 10%
UK 1 815 19% 3%
Uzbekistan 1 780 72% 3%
Kazakhstan 1 727 -1% 3%
The Netherlands 1 639 -67% 2%
Turkmenistan 1 067 38% 2%
Lithuania 817 28% 1%
Other 6 401 10% 10%
Total 66 074 3% 100%

AGM of AS Olainfarm held on June 7, this year approved operating plan of the Company and the Group, providing that Company’s sales in 2016 will reach 86 million euros, while Group’s sales will reach 100 million euros.  According to these preliminary sales numbers, in nine months of 2016 seventy-seven percent of planned annual Company’s sales and 79% percent of planned annual Group’s sales have been attained.

 JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

         Information prepared by:                    Salvis Lapins          JSC Olainfarm          Member of the Management Board          Rupnicu iela 5, Olaine, Latvia, LV 2114          Phone: +371 6 7013 717          Fax: +371 6 7013 777          E-mail: Salvis.Lapins@olainfarm.lv

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Comprehensive Update on Voting Rights and Share Capital Status

Updated Category News Views 63

URW SE stirred the pot back in September when they updated their voting rights and share capital. With a hefty total of 139,370,486 shares, this company is a real heavyweight in the European market. Shareholders can flex some serious muscle when it comes to company decisions. It's not just about holding shares; it's about wielding influence where it counts. Voting Rights:...

Continue Reading
Veteran Realtor Kate Johnson Earns Inner Circle Honor

Updated Category News Views 10

Decades of Real Estate Mastery under Kate Johnson's Belt In a world where the real estate market twists and turns like a seasoned poker player, Kate Johnson stands tall as a beacon of consistency and trust. Over five decades—yes, you heard it right, more than 51 years—she's been slicing through the complexity of the residential real estate landscape like a hot knife...

Continue Reading
JPMorgan Supports Homeowners Affected by Wildfires

Updated Category News Views 164

JPMorgan Chase Assists Homeowners During Wildfire Crisis In response to the recent wildfires impacting many communities, JPMorgan Chase (NYSE: JPM) has stepped up to offer significant support to its mortgage customers. The bank's home lending unit has introduced a disaster forbearance program specifically designed to assist homeowners affected by these devastating events....

Continue Reading
Investigation Launched on Brookline Bancorp Sale to Berkshire

Updated Category News Views 205

Halper Sadeh LLC Investigates Brookline Bancorp's Sale In a significant move that has caught the attention of investors and financial experts alike, Halper Sadeh LLC has announced its investigation regarding the sale of Brookline Bancorp, Inc. (NASDAQ: BRKL) to Berkshire Hills Bancorp, Inc. This is regarding whether the terms of the sale—0.42 shares of Berkshire common...

Continue Reading
Investigating SARS-CoV-2: Understanding Orphan Genes Role

Updated Category News Views 217

Orphan Genes and COVID-19 Severity The recent discoveries related to orphan genes in the SARS-CoV-2 virus signify a promising avenue for advancing our understanding of COVID-19. Researchers from an international collaborative team have identified an orphan gene within the virus that plays a crucial role in determining the severity of COVID-19. This research could not only...

Continue Reading